Law360: Life Sciences /lifesciences?utm_source=rss&utm_medium=rss&utm_campaign=section Latest articles for: Life Sciences Copyright 2025 ÃÛÌÒÊÓÆµ. en-US Thu, 10 Jul 2025 23:22:24 +0000 Chhabria's Privacy Ruling An 'Outlier,' Judge Tells Tech Giants /lifesciences/articles/2363465?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363465 Google and Meta urged U.S. District Judge Araceli Martínez-Olguín on Thursday to toss putative class claims alleging the companies unlawfully collected information from website users buying erectile dysfunction medication, pointing in part to a ruling on intent from her Northern District colleague, which the judge called an "outlier." Thu, 10 Jul 2025 21:35:33 +0000 Boehringer Wins Another Zantac Cancer Trial In Illinois /lifesciences/articles/2363507?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363507 Boehringer Ingelheim notched another Zantac cancer trial win in Illinois state court this week, after a jury rejected a prostate cancer patient's claim that his seven-year use of the brand-name heartburn drug played a role in his diagnosis. Thu, 10 Jul 2025 21:22:43 +0000 Execs Of Device Co. Made $6M From Insider Trading, Suit Says /lifesciences/articles/2363333?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363333 Five executives for electrotherapy device maker Zynex Inc. were hit with a derivative suit Wednesday in Colorado federal court saying they inflated the company's stock price to cash out on shares valued at more than $6 million. Thu, 10 Jul 2025 20:43:31 +0000 Fed. Circ. Backs Novartis PTAB Win Over Shilpa MS Patent /lifesciences/articles/2363374?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363374 The Federal Circuit on Thursday issued a one-word order affirming a Patent Trial and Appeal Board decision invalidating claims in a Shilpa Pharma Inc. patent that it has accused Novartis Pharmaceuticals Corp. of infringing with the drugmaker's multiple sclerosis drug. Thu, 10 Jul 2025 19:45:44 +0000 Vax Refuser Tells Jury Red Cross Mandate Was 'Unsettling' /lifesciences/articles/2363223?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363223 A former nurse for the American Red Cross said the organization's requirement that employees receive a COVID-19 vaccine was "unsettling" to her and led to physical manifestations of stress, as she testified before a federal jury on Thursday that she believed receiving the injection went against her religious beliefs. Thu, 10 Jul 2025 18:57:03 +0000 WilmerHale, US Trustee Spar Over Work In 23andMe Ch. 11 /lifesciences/articles/2363208?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363208 The U.S. Trustee's Office argued Thursday the consumer privacy ombudsman in genetic testing company 23andMe's Chapter 11 shouldn't be allowed to hire lawyers from WilmerHale over conflict of interest concerns the firm disputed, an issue the presiding Missouri bankruptcy judge promised to rule on promptly. Thu, 10 Jul 2025 18:50:58 +0000 High Court Must Overrule Outdated Patent Eligibility Doctrine /lifesciences/articles/2362465?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362465 A certiorari petition should directly ask the U.S. Supreme Court to correct its 1972 patent decision in Gottschalk v. Benson, the critical point where patent eligibility law veered from the statutory text toward judicial policymaking, says Robert Greenspoon at Dunlap Bennett. Thu, 10 Jul 2025 16:43:45 +0000 Jazz Looks To Block Avadel From Asking For Sleep Drug OK /lifesciences/articles/2363204?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363204 Jazz Pharmaceuticals wants a Delaware federal judge to block Avadel CNS Pharmaceuticals from seeking U.S. Food and Drug Administration approval for its Lumryz drug to treat the sleep disorder idiopathic hypersomnia, after the Federal Circuit sent the case back to the lower court. Thu, 10 Jul 2025 13:26:30 +0000 Playing The Violin Makes Me A Better Lawyer /lifesciences/articles/2339955?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2339955 Playing violin in a string quartet reminds me that flexibility, ambition, strong listening skills, thoughtful leadership and intentional collaboration are all keys to a successful legal practice, says Julie Park at MoFo. Thu, 10 Jul 2025 12:11:22 +0000 AbbVie Pays Up To $2B For Oncology Licensing Agreement /lifesciences/articles/2363147?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2363147 Pharmaceutical giant AbbVie Inc. on Thursday announced an up to $2 billion exclusive licensing agreement with Covington & Burling LLP-advised IGI Therapeutics SA for rights to its lead oncology and autoimmune diseases investigational asset. Wed, 09 Jul 2025 22:35:40 +0000 Google Notches Deal With Flo Users Ahead Of Privacy Trial /lifesciences/articles/2362901?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362901 Google and users of the menstrual cycle tracking app Flo have reached a deal to resolve claims that the tech giant used a data analytics tool to unlawfully retrieve their sensitive health data, releasing the company from a July 21 trial that's still scheduled to proceed with respect to similar privacy claims being pressed against the app maker and Meta. Wed, 09 Jul 2025 20:13:34 +0000 J&J Unit Owes $76.6M For Ending AI Tissue Imaging Deal /lifesciences/articles/2362978?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362978 A New York federal judge held Tuesday that Johnson & Johnson's Ethicon unit owes ChemImage Corp. $76.6 million after unilaterally ending their deal to develop in-surgery artificial intelligence imaging techniques, adopting a 17% discount rate on intellectual property impairment damages proposed by ChemImage as opposed to Ethicon's proposed 40% rate. Wed, 09 Jul 2025 18:31:06 +0000 Venture-Backed MedTech Firm Shoulder Innovations Files IPO /lifesciences/articles/2362124?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362124 Venture-backed medical device firm Shoulder Innovations Inc. has filed plans for an initial public offering, represented by Latham & Watkins LLP and underwriters' counsel Cooley LLP, marking the latest health-focused technology startup to test public markets. Wed, 09 Jul 2025 18:17:41 +0000 J&J Seeks To Toss 'Nowhere Close' Band-Aid PFAS Suit In NJ /lifesciences/articles/2362699?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362699 Johnson & Johnson and Kenvue Inc. are urging a New Jersey federal court to toss a proposed class action alleging that the companies have not disclosed to the public that PFAS "forever chemicals" are present in unsafe amounts in Band-Aid brand adhesive bandages, arguing that the plaintiffs come "nowhere close" to stating a plausible claim. Wed, 09 Jul 2025 18:15:10 +0000 The State Of AI Adoption In The Patent Field /lifesciences/articles/2361591?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2361591 The use of generative artificial intelligence in patent-related practices has lagged behind early predictions, which may be explained by a number of core concerns that organizations must address before seriously considering adoption, say attorney Michael Drapkin and leadership coach Michael Colacchio. Wed, 09 Jul 2025 17:35:07 +0000 Purdue Case Could Transform Patent Obviousness Analyses /lifesciences/articles/2362420?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362420 If accepted for review by the U.S. Supreme Court, Purdue Pharma v. Accord Healthcare — concerning whether Purdue's abuse-deterrent opioid formulation patents were invalid as obvious — could significantly shift how courts weigh secondary considerations in patent obviousness analyses, say attorneys at Lathrop. Wed, 09 Jul 2025 17:13:42 +0000 Sandoz, Buyers Defend $275M Deal Amid State Objections /lifesciences/articles/2362662?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362662 Counsel for consumers, insurers and others urged a Pennsylvania federal court on Tuesday to approve Sandoz and its subsidiaries' $275 million deal settling claims it conspired with other companies to fix some generic drug prices, with Sandoz separately calling states' objections "a paternalistic desire to control private class action settlements." Wed, 09 Jul 2025 16:41:18 +0000 Fed. Circ. Cements Arthrex PTAB Wins Over Medical Device IP /lifesciences/articles/2362803?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362803 The Federal Circuit on Wednesday affirmed without explanation decisions from the Patent Trial and Appeal Board invalidating claims in a group of medical device patents challenged by Arthrex Inc. Wed, 09 Jul 2025 15:39:37 +0000 10th Circ. Won't Rule On Immunity In Dental Dispute /lifesciences/articles/2362449?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2362449 The Tenth Circuit has declined to grant a dental products company immunity from a rival's defamation claims, saying it can't yet rule on the issue since the district court's denial of immunity did not turn on a legal question. Wed, 09 Jul 2025 13:56:54 +0000 Federal Regs Order May Spell Harsher FDCA Enforcement /lifesciences/articles/2360200?utm_source=rss&utm_medium=rss&utm_campaign=section /lifesciences/articles/2360200 A recent executive order aimed at reducing criminal prosecutions of those who unknowingly violate complex federal regulations may actually lead to more aggressive felony indictments under the Federal Food, Drug and Cosmetic Act, but companies and executives can mitigate risks by following several key principals, say attorneys at McGuireWoods.